PMID- 32405876
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230919
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 11
IP  - 6
DP  - 2020 Jun
TI  - Canagliflozin for the Treatment of Diabetic Kidney Disease and Implications for 
      Clinical Practice: A Narrative Review.
PG  - 1237-1250
LID - 10.1007/s13300-020-00826-w [doi]
AB  - Type 2 diabetes mellitus (T2DM) affects millions of people worldwide, elevating 
      their risk of developing a range of complications, including chronic kidney 
      disease (CKD). People with T2DM and CKD (i.e., diabetic kidney disease, DKD) have 
      an increased risk of progressing to end-stage kidney disease (ESKD), experiencing 
      cardiovascular complications, and premature death. Despite this, DKD is primarily 
      addressed through management of risk factors, and there are few pharmaceutical 
      treatments capable of reversing or delaying disease progression. Canagliflozin is 
      a sodium glucose co-transporter 2 inhibitor that was initially developed as a 
      blood glucose-lowering agent for people with T2DM. Evidence from clinical trials 
      of canagliflozin in people with T2DM, as well as evidence from cardiovascular 
      outcomes trials in people with T2DM and high cardiovascular risk, provided 
      preliminary evidence suggesting that it may also have beneficial renal effects. 
      The Canagliflozin and Renal Events in Diabetes with Established Nephropathy 
      Clinical Evaluation (CREDENCE) trial was a dedicated renal outcomes trial of 
      canagliflozin that assessed its renal effects in people with DKD. Overall, the 
      CREDENCE trial demonstrated that canagliflozin improves renal outcomes and slows 
      early disease progression in people with DKD. These data supported the approval 
      of canagliflozin for the treatment DKD, the first new treatment in almost 
      20 years; therefore, it is important for clinicians to understand how to 
      implement this treatment in their clinical practice.
FAU - Kruger, Davida
AU  - Kruger D
AD  - Henry Ford Health System, Detroit, MI, USA. dkruger1@hfhs.org.
FAU - Valentine, Virginia
AU  - Valentine V
AD  - Clinica La Esperanza, Albuquerque, NM, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200513
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC7261301
OTO - NOTNLM
OT  - Canagliflozin
OT  - Cardiovascular disease
OT  - Diabetic kidney disease
OT  - Randomized trials
OT  - Sodium glucose co-transporter 2 inhibitor
OT  - Type 2 diabetes
EDAT- 2020/05/15 06:00
MHDA- 2020/05/15 06:01
PMCR- 2020/05/13
CRDT- 2020/05/15 06:00
PHST- 2020/03/12 00:00 [received]
PHST- 2020/05/15 06:00 [pubmed]
PHST- 2020/05/15 06:01 [medline]
PHST- 2020/05/15 06:00 [entrez]
PHST- 2020/05/13 00:00 [pmc-release]
AID - 10.1007/s13300-020-00826-w [pii]
AID - 826 [pii]
AID - 10.1007/s13300-020-00826-w [doi]
PST - ppublish
SO  - Diabetes Ther. 2020 Jun;11(6):1237-1250. doi: 10.1007/s13300-020-00826-w. Epub 
      2020 May 13.